Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Alonso García

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nefrologia|June 18, 2021
Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosisMarina Almenara Tejederas, Fabiola Alonso García, Wenceslao Adrián Aguilera Morales, et al.
Case Reports in Nephrology and Dialysis|July 17, 2024
Xanthogranulomatous Pyelonephritis in Peritoneal DialysisJavier Burgos Martín, Marina Almenara Tejederas, Fabiola Alonso García, et al.
Nefrologia|September 26, 2022
Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosisMarina Almenara-Tejederas, Fabiola Alonso-García, Wenceslao Adrián Aguillera-Morales, et al.
Nefrologia|April 17, 2024
Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatmentFrancisco José de la Prada Álvarez, Melissa Cintra Cabrera, Marina Almenara Tejederas, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nefrologia|June 18, 2021
Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosisMarina Almenara Tejederas, Fabiola Alonso García, Wenceslao Adrián Aguilera Morales, et al.
Case Reports in Nephrology and Dialysis|July 17, 2024
Xanthogranulomatous Pyelonephritis in Peritoneal DialysisJavier Burgos Martín, Marina Almenara Tejederas, Fabiola Alonso García, et al.
Nefrologia|September 26, 2022
Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosisMarina Almenara-Tejederas, Fabiola Alonso-García, Wenceslao Adrián Aguillera-Morales, et al.
Nefrologia|April 17, 2024
Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatmentFrancisco José de la Prada Álvarez, Melissa Cintra Cabrera, Marina Almenara Tejederas, et al.
Pageof 1